FFP2 CAN6 Anticancer Agents 2 2024
Thursday, 22 February 2024
8:43 PM
FFP2 CAN6
Anticance...
New Section 1 Page 1
New Section 1 Page 2
New Section 1 Page 3
New Section 1 Page 4
New Section 1 Page 5
New Section 1 Page 6
New Section 1 Page 7
New Section 1 Page 8
New Section 1 Page 9
New Section 1 Page 10
New Section 1 Page 11
New Section 1 Page 12
New Section 1 Page 13
New Section 1 Page 14
New Section 1 Page 15
New Section 1 Page 16
New Section 1 Page 17
New Section 1 Page 18
New Section 1 Page 19
New Section 1 Page 20
Majority of cellular effects of oestrogen are
are mediated by intracellular estrogen receptors (ER)
Upon binding of estrogen to ER in the cytoplasm,
a conformational change (induces receptor dimerization) is then translocated to
the nucleus, where it binds to specific region on chromatin.
Thereby activating the transcription of specific genes,
leading to increased cell growth and proliferation
New Section 1 Page 21
New Section 1 Page 22
Then the metabolite will bind to an Androgen
Receptor (AR)
This hormone receptor complex will the
dimerize with another hormone bound
receptor and translocate into the nucleus,
binding to specific DNA sequences, thus
triggering expression of genes involving cell
growth & proliferation.
New Section 1 Page 23
Endothelial cells form a single cell layer that lines all blood vessels and regulates exchanges between the bloodstream
and the surrounding tissues. Signals from endothelial cells organize the growth and development of connective tissue
cells that form the surrounding layers of the blood-vessel wall.
Trastuzumab is a monoclonal antibody against human epidermal growth factor receptor 2 (HER2). Trastuzumab
binds to an extracellular domain of this receptor and inhibits HER2 homodimerization, thereby preventing HER2mediated signaling.
New Section 1 Page 24